Rostov Cancer Research Institute

Rostov-na-Donu, Russia

Rostov Cancer Research Institute

Rostov-na-Donu, Russia
SEARCH FILTERS
Time filter
Source Type

Kit O.I.,Rostov Cancer Research Institute | Vodolazhskiy D.I.,Rostov Cancer Research Institute | Kolesnikov E.N.,Rostov Cancer Research Institute | Timoshkina N.N.,Rostov Cancer Research Institute
Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry | Year: 2017

Adenocarcinoma and squamous cell carcinoma are the most common types of esophageal malignant tumors. Their constant tendency to the increase in morbidity and high mortality rate underlie importance of the search for new biomarkers that complement and improve the early diagnosis of this disease. Despite significant efforts undertaken in this field the only marker of esophageal cancer, the ERBB2/HER2 status, is used in routine clinical practice. This review summarizes data on epigenetic markers characterizing aberrant methylation of the genome, which may be useful for early detection of esophageal cancer, prognosis and/or prediction of response to treatment. The development of new high-throughput technologies of genome-wide screening, such as BeadChip array and immunoprecipitation followed by sequencing, used not only for genome-wide genotyping, but also for the analysis of transcriptome and methylome, provides a comprehensive picture of genetic and epigenetic changes during tumorigenesis. © 2017, Pleiades Publishing, Ltd.


Todorov S.S.,Rostov Cancer Research Institute | Kit O.I.,Rostov Cancer Research Institute
Arkhiv Patologii | Year: 2012

The paper considers the current aspects of the morphology, immunohistochemistry, molecular biology of liposarcomas. Particular attention is given to the embryogenesis of liposarcomas and to problems in the immunohistochemical diagnosis of these neoplasms. There is evidence that TLS-CHOP is involved in the PNA processing of liposarcoma cells. Prospects for the diagnosis and treatment of malignant mesenchymal tumors are discussed.


Garkavi L.H.,Rostov Cancer Research Institute | Zhukova G.V.,Rostov Cancer Research Institute | Shikhliarova A.I.,Rostov Cancer Research Institute | Evstratova O.F.,Rostov Cancer Research Institute | And 6 more authors.
Biophysics (Russian Federation) | Year: 2014

This paper presents a brief overview of the results of original research of biological responses to the effect of low doses of substances exhibiting cytostatic and regulatory effects, as well as to weak electromagnetic radiation of different frequency ranges. The possibility of obtaining pronounced antitumor, antistress, and geroprotective effects was shown. The relation between the systemic mechanisms of implementation of these effects and structural rearrangements in biological fluids, as well as areas that seem promising for optimization of the therapeutic properties of informational effect, are discussed. © 2014, Pleiades Publishing, Inc.


PubMed | Rostov Cancer Research Institute
Type: Review | Journal: Biomeditsinskaia khimiia | Year: 2016

Adenocarcinoma and squamous cell carcinoma are the most common types of esophageal cancer with a constant tendency to increase the incidence of growth on the background of the high mortality, which makes particularly the development of new biomarkers that complement and improve the early diagnosis of this disease. Despite the impressive number of studies in routine clinical practice is used only marker of esophageal cancer - ERBB2/HER2 status. This review summarizes data on the identified epigenetic markers of the aberrant methylation of the genome, which may be useful for early detection of esophageal cancer, prognosis estimation and / or prediction of response to treatment. The development of new high-tech genome-wide screening, such as beadarray and immunoprecipitation sequencing method used for the wideband genotyping, but for the analysis of transcriptome and metilom, provides a comprehensive picture of genetic and epigenetic changes during tumorigenesis. Note the need to verify the most biomarkers on large representative samples for the development of valid diagnostic panels, suitable for large-scale screening of risk groups.

Loading Rostov Cancer Research Institute collaborators
Loading Rostov Cancer Research Institute collaborators